Xpert MTB/RIF Ultra 检测结核分枝杆菌及利福平耐药的前瞻性多中心诊断准确性研究
这项前瞻性多中心诊断准确性研究在8个国家纳入1753例有肺结核症状的成人,比较Xpert Ultra与Xpert检测结核及利福平耐药的性能,以培养和药敏试验为参考标准。Xpert Ultra对涂片阴性、HIV阳性及所有培养阳性患者的敏感性均优于Xpert,但特异性略有下降,利福平耐药检测两者相似。
要点
- Xpert Ultra对涂片阴性培养阳性结核的敏感性为63%,高于Xpert的46%。
- Xpert Ultra对HIV阳性培养阳性患者的敏感性为90%,高于Xpert的77%。
- Xpert Ultra总体特异性96%低于Xpert的98%,有结核病史者特异性93%。
核心结论
- 对于结核病例检测,Xpert Ultra在低菌量患者和HIV感染者中的敏感性优于Xpert,但敏感性提高以特异性下降为代价。
研究设计与样本
- 前瞻性、多中心诊断准确性研究,在8个国家招募有肺结核症状的成人,最终1753例纳入分析,其中病例检测组1439例,耐多药风险组314例。
- 每位参与者在2个不同日提供至少3份痰标本,同一痰标本的Xpert与Xpert Ultra性能以培养和药敏试验为参考标准进行比较。
主要发现
- 在137例涂片阴性且培养阳性的参与者中,Xpert Ultra和Xpert的敏感性分别为63%和46%,差异17%(95%CI 10至24)。
- Xpert Ultra和Xpert在检测利福平耐药方面表现相似。
关键数值与推荐
- 涂片阴性培养阳性:Xpert Ultra敏感性63% vs Xpert 46%,差异17%(95%CI 10至24)。
- 有结核病史者特异性:Xpert Ultra 93% vs Xpert 98%。
临床怎么用
- 在低菌量肺结核或HIV感染者中,可优先考虑Xpert Ultra以提高结核检出敏感性。
- 需注意Xpert Ultra特异性略低,尤其在有结核病史者中,阳性结果应结合临床评估。
- 利福平耐药检测方面Xpert Ultra与Xpert性能相似,可按现有流程选用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Xpert MTB/RIF assay is an automated molecular test that has improved the detection of tuberculosis and rifampicin resistance, but its sensitivity is inadequate in patients with paucibacillary disease or HIV. Xpert MTB/RIF Ultra (Xpert Ultra) was developed to overcome this limitation. We compared the diagnostic performance of Xpert Ultra with that of Xpert for detection of tuberculosis and rifampicin resistance. METHODS: In this prospective, multicentre, diagnostic accuracy study, we recruited adults with pulmonary tuberculosis symptoms presenting at primary health-care centres and hospitals in eight countries (South Africa, Uganda, Kenya, India, China, Georgia, Belarus, and Brazil). Participants were allocated to the case detection group if no drugs had been taken for tuberculosis in the past 6 months or to the multidrug-resistance risk group if drugs for tuberculosis had been taken in the past 6 months, but drug resistance was suspected. Demographic information, medical history, chest imaging results, and HIV test results were recorded at enrolment, and each participant gave at least three sputum specimen on 2 separate days. Xpert and Xpert Ultra diagnostic performance in the same sputum specimen was compared with culture tests and drug susceptibility testing as reference standards. The primary objectives were to estimate and compare the sensitivity of Xpert Ultra test with that of Xpert for detection of smear-negative tuberculosis and rifampicin resistance and to estimate and compare Xpert Ultra and Xpert specificities for detection of rifampicin resistance. Study participants in the case detection group were included in all analyses, whereas participants in the multidrug-resistance risk group were only included in analyses of rifampicin-resistance detection. FINDINGS: Between Feb 18, and Dec 24, 2016, we enrolled 2368 participants for sputum sampling. 248 participants were excluded from the analysis, and 1753 participants were distributed to the case detection group (n=1439) and the multidrug-resistance risk group (n=314). Sensitivities of Xpert Ultra and Xpert were 63% and 46%, respectively, for the 137 participants with smear-negative and culture-positive sputum (difference of 17%, 95% CI 10 to 24); 90% and 77%, respectively, for the 115 HIV-positive participants with culture-positive sputum (13%, 6·4 to 21); and 88% and 83%, respectively, across all 462 participants with culture-positive sputum (5·4%, 3·3 to 8·0). Specificities of Xpert Ultra and Xpert for case detection were 96% and 98% (-2·7%, -3·9 to -1·7) overall, and 93% and 98% for patients with a history of tuberculosis. Xpert Ultra and Xpert performed similarly in detecting rifampicin resistance. INTERPRETATION: For tuberculosis case detection, sensitivity of Xpert Ultra was superior to that of Xpert in patients with paucibacillary disease and in patients with HIV. However, this increase in sensitivity came at the expense of a decrease in specificity. FUNDING: Government of Netherlands, Government of Australia, Bill & Melinda Gates Foundation, Government of the UK, and the National Institute of Allergy and Infectious Diseases.
引用
- Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2017. PMID: 29198911. doi:10.1016/S1473-3099(17)30691-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。